Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plumula nelumbinis
- Development stage
- Preclinical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Topical
01
Overview
Plumula nelumbinis is the green embryo of the mature seeds of the lotus plant (*Nelumbo nucifera* Gaertn). It is a well-known traditional Chinese medicine (TCM) and functional food, commonly consumed as a tea or dietary supplement. The extract is rich in bioactive compounds, particularly bisbenzylisoquinoline alkaloids such as liensinine, neferine, and isoliensinine, as well as flavonoids like schaftoside and rhoifolin. Research indicates that Plumula nelumbinis possesses a wide range of pharmacological activities, including cardiovascular protection (antihypertensive and anti-remodeling effects), anti-inflammatory, antioxidant, and anti-tumor properties. It has been investigated for its potential in treating vascular diseases, sepsis-induced liver injury, atopic dermatitis, and various cancers (such as non-small cell lung cancer and pancreatic cancer) by modulating signaling pathways like Nrf2/HO-1, MAPK/NF-κB, and AKT/mTOR. Notably, it contains higenamine, a substance prohibited in sports by the World Anti-Doping Agency (WADA).
- Other names
- lotus seed embryoNelumbo nucifera embryoLian Zi Xin莲子心
02
Targets
NF-κBCACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)mTOR (Mammalian target of rapamycin kinase)HMOX1 (Heme oxygenase 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on plumula nelumbinis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plumula nelumbinis.